Saw Palmetto Treatment for Prostatitis: A Systematic Review of the Literature
Bibliographic record
Abstract
Purpose: This systematic review was conducted to determine the safety and efficacy of Serenoa repens extract (saw palmetto extract) in treating chronic prostatitis, as compared with existing treatment regimens and placebo. Methods: Adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a systematic query was performed across multiple databases in December 2021 to identify relevant studies. The selection criteria focused on studies evaluating the treatment regimens, safety, and efficacy of saw palmetto in treating chronic prostatitis/chronic pelvic pain syndrome. Results: Of 259 references, 21 studies encompassing 1666 patients were selected. These studies included a range of trial types, with a mean follow-up period of approximately 6.975 months. Saw palmetto extract showed improved symptom relief compared with placebo, with mixed results when compared with alpha-blockers or 5-ARIs. Multimodal treatments, especially those including saw palmetto extract alongside antibiotics, displayed better efficacy in managing both Category II and Category III prostatitis. Conclusion: Saw palmetto extract provides symptom relief in patients with chronic prostatitis. Although monotherapy exhibited certain benefits over placebo, its best efficacy was observed when integrated into multimodal treatment regimens, particularly with antibiotics for Category II prostatitis. Future research may unveil specific adjuncts that enhance the therapeutic outcomes of regimens containing saw palmetto extract.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.005 | 0.015 |
| Meta-epidemiology (narrow) | 0.001 | 0.001 |
| Meta-epidemiology (broad) | 0.008 | 0.008 |
| Bibliometrics | 0.006 | 0.007 |
| Science and technology studies | 0.001 | 0.001 |
| Scholarly communication | 0.002 | 0.002 |
| Open science | 0.001 | 0.001 |
| Research integrity | 0.002 | 0.001 |
| Insufficient payload (model declined to judge) | 0.005 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".